Diseases leading to immune activation and autoinflammatory phenotypes may provide a reservoir of potentially druggable pathways for optimizing immune adjuvants or boosting antitumor immune responses. Now, Xia et al. report that lipophilic statins or biphosphonates, targeting the mevalonate pathway, act as efficient vaccine adjuvants and synergize with anti-PD1 against cancer.
The medical community might not realize that two types of drugs that are among the most frequently prescribed globally-statins to lower blood cholesterol level and bisphosphonates to treat osteoporosis-target the same mevalonate (MVA) pathway, an essential metabolic pathway responsible for the production of cholesterol, as well as that of isoprenoid lipids substrates for protein prenylation (Goldstein and Brown, 1990) . Prenylation is a post-translational modification involving the transfer of farnesyl or geranylgeranyl lipid groups on characteristic carboxy-terminal CAAX motifs of proteins (Wang and Casey, 2016) . Such prenylation of small GTPases of the Rab, Ras, and Rho families is critical for their internal cell membrane anchorage and for a wide variety of critical cell processes, including integrin signaling, endosomal trafficking, membrane ruffling, and apoptosis (Machesky and Hall, 1997) . A link between MVA and autoinflammatory phenotypes was suspected when it was realized that biallelic lossof-function mutations in the MVK gene encoding MVA kinase, a key enzyme of the MVA pathway leading to MVA phosphorylation, are present in a rare autoinflammatory disease belonging to the group of periodic fever syndromes: the hyperimmunoglobulinemia D syndrome (HIDS) (Drenth et al., 2000) . This disease is associated with repeated episodes of fever, rash, and gastrointestinal inflammation symptoms of various intensities. This autoinflammatory constitutional disease is thought to be mostly linked to a direct potentiation of pyrin-inflammasome (Manthiram et al., 2017) .
In this issue of Cell, Xia et al. (2018) now challenge the hypothesis of a sole direct effect of the MVA pathway on inflammation and identify a new mechanism underlying the pro-inflammatory potential of smallmolecule inhibitors of different enzymes located either upstream of MVK in the MVA pathway-i.e., the high-mobility group coenzyme A (HMG-CoA) reductase-or downstream of MVK-i.e., the farnesyldiphosphate synthate (FPPS) and geranylgernayldiphosphate synthate (GGPPS). They show that pharmacological inhibition of the MVA pathway, achieved with lipophilic HMG-CoA reductase inhibitors (i.e., statins), a newly rationally designed FPPS inhibitor (i.e., bisphosphonate TH-Z93), and a GGPPS inhibitor (i.e., TH-Z145), but not a squalene synthase inhibitor involved in the synthesis of cholesterol downstream of MVA, act as potent vaccine adjuvants, as evaluated in an elegant series of experiments designed to monitor the ability of these compounds to potentiate vaccine-specific protective antibody titers in murine models. The authors find that MVA pathway inhibitors, instead of triggering adaptive immunity by inducing CD80/CD86/MHC-II expression or cytokine release in antigen-presenting cells (blood-derived dendritic cells) as done by lipopolysaccharide (LPS) or other pathogen-associated patterns (PAMPs), regulate the levels of proteins involved in endocytic vesicle trafficking and organization. This effect is independent of the interleukin (IL)-1-beta production and the pyrin-inflammasome but is rather related to a slowdown of endosome maturation leading to increased surface availability of antigenic epitopes. This increased antigen occupation on dendritic cells results in boosted CD4 + responses, as well as CD8 + responses. To directly demonstrate the role of GGPPS inhibition in the observed phenotypes, the authors administer GGPP, the GGPPS product, and show that it blocked several of the effects induced by MVA pathway inhibitors. In addition, GGPSS gene deletion in dendritic cells leads to reduced endosome and lysosome fusion. The authors identify the prenylated effector proteins by showing that depleting Rab5, but not several other Rab members, blocks endosomal maturation and increases antigen presentation. The specific contribution of Rab5, however, warrants further investigation-for instance, by analyzing the consequences of mutating the CAAX motif of Rab5. Finally, the lipophilic statin simvastatin, having a pronounced adjuvant effect in two murine tumor vaccine models, also demonstrates a strong synergy when used in association with an antitumor immunotherapy targeting the programmed cell death (PD1) checkpoint inhibitor. The fact that the adjuvant effect of simvastatin is not limited to humoral immunity with a boost in immunoglobulin G (IgG) production but also enhances cellular immunity with increased Th1 and cytolytic functions, known to be of paramount importance in anticancer response, is a major advantage over usual vaccine adjuvants with regards to anticancer immunotherapy.
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Altogether, the results of Xia et al. offer new perspectives on MVA-inhibitor mechanisms of action and potential therapeutic uses. Optimizing immune adjuvant by acting on dendritic cells' endosomal maturation kinetics is indeed a highly innovative concept. Therapeutic use of MVA-pathway inhibitors for anti-infectious vaccines or in the aim of boosting antitumor responses in combination with anti-PD1 or PDL-1 antibodies is an attractive objective.
Although neither statins nor bisphosphonates were initially supposed to have any effect on tumor biology, several epidemiological studies suggest that these two drug families might have an antitumor effect (Altwairgi, 2015; Gnant and Clé zardin, 2012; Iannelli et al., 2018) . Some hypotheses supported by preclinical studies put forward a direct antitumor effect of the MVA pathway blockade via its interaction with essential oncogenic actors or pathways such as p53, MYC, PI3-kinase, and MAP-kinase pathways (Iannelli et al., 2018) . The present work, demonstrating that these drugs might also act via an indirect immunotherapeutic effect, will probably result in a strong resurgence of interest in exploring the antitumor effect of MVA-pathway inhibitors in cancer therapy.
However, the dosing, as well as the mode of administration of such inhibitors, will probably constitute critical issues. As suggested by the authors, oral administration of statins might not be the optimized way to induce a strong adjuvant effect as compared with intradermal, subcutaneous, or intratumor approaches. Importantly, immunosuppressive effects have been observed with higher doses of MVA inhibitor (Ghittoni et al., 2006) . One can suppose that at high concentrations or in different environmental contexts, a strong endosomal maturation slowdown could result in a totally arrested maturation that could lead to a subsequent decrease of antigen presentation.
Finally, this work constitutes a solid preclinical basis to raise hopes toward new and exciting avenues that might be capable of enhancing both our anti-infection and antitumor immune defenses with a potential huge impact on the collectivity.
Mutation frequencies vary along the genome, but the factors determining this variability are only partially understood. Pich et al. unravel a 10 bp periodicity in mutation rates at nucleosome-proximal regions that follows minor groove orientation. Opposing differential DNA damage and repair processes could shape genetic divergence irrespective of selection.
Eukaryotic DNA is tightly packed into chromatin by wrapping around nucleosomes consisting of histone octamers. To facili-tate this compaction, the DNA double helix sharply bends every helical repeat in a 10 bp periodicity, when the DNA major groove faces toward the nucleosome core (Richmond and Davey, 2003) . Consistently, A/T di-nucleotides (WW) are favored
